Viridian Therapeutics, Inc.\DE (VRDN) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Viridian Therapeutics, Inc.\DE (VRDN) over the last 9 years, with Q3 2025 value amounting to $0.04.
- Viridian Therapeutics, Inc.\DE's Debt to Equity rose 4317.91% to $0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.04, marking a year-over-year increase of 4317.91%. This contributed to the annual value of $0.03 for FY2024, which is 3295.96% down from last year.
- Per Viridian Therapeutics, Inc.\DE's latest filing, its Debt to Equity stood at $0.04 for Q3 2025, which was up 4317.91% from $0.04 recorded in Q2 2025.
- Viridian Therapeutics, Inc.\DE's Debt to Equity's 5-year high stood at $0.05 during Q4 2023, with a 5-year trough of $0.03 in Q3 2024.
- Moreover, its 3-year median value for Debt to Equity was $0.04 (2024), whereas its average is $0.04.
- In the last 5 years, Viridian Therapeutics, Inc.\DE's Debt to Equity crashed by 3295.96% in 2024 and then soared by 4317.91% in 2025.
- Quarter analysis of 3 years shows Viridian Therapeutics, Inc.\DE's Debt to Equity stood at $0.05 in 2023, then crashed by 32.96% to $0.03 in 2024, then surged by 35.53% to $0.04 in 2025.
- Its Debt to Equity was $0.04 in Q3 2025, compared to $0.04 in Q2 2025 and $0.03 in Q1 2025.